Use: Labeled indications
SmPC 4.1 Therapeutic indications EU SmPC (EMA)
DuoTrav is indicated in adults for the decrease of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta blockers or prostaglandin analogues (see section 5.1).
Contraindications
SmPC 4.3 Contraindications EU SmPC (EMA)
Hypersensitivity to the active substances, or to any of the excipients listed in section 6.1. Hypersensitivity to other beta blockers. Reactive airway disease including bronchial asthma, or a history of bronchial asthma, severe chronic obstructive pulmonary disease. Sinus bradycardia, sick sinus syndrome, including sino-atrial block, second- or third-degree atrioventricular block not controlled with pacemaker. Overt cardiac failure, cardiogenic shock. Severe allergic rhinitis and corneal dystrophies.
Dosing: Adult
SmPC 4.2 Posology and method of administration EU SmPC (EMA)
Posology
Use in adults, including the elderly
The dose is one drop of DuoTrav in the conjunctival sac of the affected eye(s) once daily, in the morning or evening. It should be administered at the same time each day.
If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.
Special populations
Hepatic and renal impairment No studies have been conducted with DuoTrav or with timolol 5 mg/mL eye drops in patients with hepatic or renal impairment.
Travoprost has been studied in patients with mild to severe hepatic impairment and in patients with mild to severe renal impairment (creatinine clearance as low as 14 mL/min). No dose adjustment was necessary in these patients.
Patients with hepatic or renal impairment are unlikely to require dose adjustment with DuoTrav (see section 5.2).
Paediatric population
The safety and efficacy of DuoTrav in children and adolescents below the age of 18 years have not been established. No data are available.
Method of administration
For ocular use.
The patient should remove the protective overwrap immediately prior to initial use. To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle.
When nasolacrimal occlusion is used or the eyelids are closed for 2 minutes, systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity (see section 4.4).
If more than one topical ophthalmic medicinal product is being used, the medicinal products must be administered at least 5 minutes apart (see section 4.5).
When substituting another ophthalmic antiglaucoma medicinal product with DuoTrav, the other medicinal product should be discontinued and DuoTrav should be started the following day.
Patients must be instructed to remove soft contact lenses prior to application of DuoTrav and wait 15 minutes after instillation of the dose before reinsertion (see section 4.4).
Dosing: Altered kidney function
Hepatic and renal impairment No studies have been conducted with DuoTrav or with timolol 5 mg/mL eye drops in patients with hepatic or renal impairment.
Travoprost has been studied in patients with mild to severe hepatic impairment and in patients with mild to severe renal impairment (creatinine clearance as low as 14 mL/min). No dose adjustment was necessary in these patients.
Patients with hepatic or renal impairment are unlikely to require dose adjustment with DuoTrav (see section 5.2).
Travoprost free acid and its metabolites are mainly excreted by the kidneys. Less than 2% of an ocular dose of travoprost was recovered in urine as free acid. Timolol and its metabolites are primarily excreted by the kidneys. Approximately 20% of a timolol dose is excreted in the urine unchanged and the remainder excreted in urine as metabolites.
Source: EU Summary of Product Characteristics (EMA), DuoTrav, revised February 5, 2026, reproduced with acknowledgment of the source (verbatim). This generic has no US FDA label.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric population (SmPC 4.2) EU SmPC (EMA)
Paediatric population
The safety and efficacy of DuoTrav in children and adolescents below the age of 18 years have not been established. No data are available.
Dosing: Older adult
Older adults (SmPC 4.2) EU SmPC (EMA)
Use in adults, including the elderly
The dose is one drop of DuoTrav in the conjunctival sac of the affected eye(s) once daily, in the morning or evening. It should be administered at the same time each day.
If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.
Dosage forms
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Timolol + Travoprost as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
DuotravTravoprost + Timolol (as maleate) | 40 mcg/5 mg per mL (0.004%/0.5% w/v) Sterile Ophthalmic Solution [Benzalkonium chloride (BAK) Free Formula]White Syndiotactic Polypropylene (SPP) Oval Droptainer with a Polypropylene (PP) Natural Dispensing Plug and a White Polypropylene (PP) Closure with Foil Overwrap x 2.5 mL (Box of 1's) and 1.5 mL (Box of 1's) as Physician’s Sample (Box of 1's) | Rx | Alcon-Couvreur NVBelgium | Importer: Novartis Healthcare Philippines, Inc. | DR-XY33940 | Mar 22, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
SmPC 4.4 Special warnings and precautions for use EU SmPC (EMA)
Systemic effects
Like other topically applied ophthalmic agents, travoprost and timolol are absorbed systemically. Due to the beta-adrenergic component, timolol, the same types of cardiovascular, pulmonary and other adverse reactions seen with systemic beta-adrenergic blocking medicinal products may occur. The incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. For information on how to reduce systemic absorption, see section 4.2.
Cardiac disorders
In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal’s angina and cardiac failure) and hypotension, therapy with beta blockers should be critically assessed and therapy with other active substances should be considered. Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions.
Due to their negative effect on conduction time, beta blockers should only be given with caution to patients with first-degree heart block.
Vascular disorders
Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud’s disease or Raynaud’s syndrome) should be treated with caution.
Respiratory disorders
Respiratory reactions, including death due to bronchospasm in patients with asthma, have been reported following administration of some ophthalmic beta blockers.
DuoTrav should be used with caution in patients with mild/moderate chronic obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk.
Hypoglycaemia/diabetes
Beta blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or in patients with labile diabetes, as beta blockers may mask the signs and symptoms of acute hypoglycaemia.
Muscle weakness
Beta-adrenergic blocking medicinal products have been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g. diplopia, ptosis and generalised weakness).
Corneal diseases
Ophthalmic beta blockers may induce dryness of eyes. Patients with corneal diseases should be treated with caution.
Choroidal detachment
Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g. timolol, acetazolamide) after filtration procedures.
Other beta-blocking agents
The effect on intra-ocular pressure or the known effects of systemic beta blockade may be potentiated when timolol is given to patients already receiving a systemic beta-blocking medicinal product. The response of these patients should be closely observed. The use of two topical beta-adrenergic blocking agents is not recommended (see section 4.5).
Surgical anaesthesia
Beta-blocking ophthalmological preparations may block systemic beta-agonist effects, e.g. of adrenaline. The anaesthetist should be informed when the patient is receiving timolol.
Hyperthyroidism
Beta blockers may mask the signs of hyperthyroidism.
Skin contact
Prostaglandins and prostaglandin analogues are biologically active substances that may be absorbed through the skin. Women who are pregnant or attempting to become pregnant should exercise appropriate precautions to avoid direct exposure to the contents of the bottle. In the unlikely event of coming in contact with a substantial portion of the contents of the bottle, thoroughly cleanse the exposed area immediately.
Anaphylactic reactions
While taking beta blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens and unresponsive to the usual dose of adrenaline used to treat anaphylactic reactions.
Concomitant therapy
Timolol may interact with other medicinal products (see section 4.5).
The use of two local prostaglandins is not recommended.
Ocular effects
Travoprost may gradually change the eye colour by increasing the number of melanosomes (pigment granules) in melanocytes. Before treatment is instituted, patients must be informed of the possibility of a permanent change in eye colour. Unilateral treatment can result in permanent heterochromia. The long-term effects on the melanocytes and any consequences thereof are currently unknown. The change in iris colour occurs slowly and may not be noticeable for months to years. The change in eye colour has predominantly been seen in patients with mixed coloured irides, i.e. blue-brown, grey-brown, yellow-brown and green-brown; however, it has also been observed in patients with brown eyes. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery in affected eyes, but the entire iris or parts of it may become more brownish. After discontinuation of therapy, no further increase in brown iris pigment has been observed.
In controlled clinical trials, periorbital and/or eyelid skin darkening in association with the use of travoprost has been reported.
Periorbital and lid changes, including deepening of the eyelid sulcus, have been observed with prostaglandin analogues.
Travoprost may gradually change eyelashes in the treated eye(s); these changes were observed in about half of the patients in clinical trials and include: increased length, thickness, pigmentation, and/or number of lashes. The mechanism of eyelash changes and their long-term consequences are currently unknown.
Travoprost has been shown to cause slight enlargement of the palpebral fissure in studies in the monkey. However, this effect was not observed during the clinical trials and is considered to be species specific.
There is no experience of DuoTrav in inflammatory ocular conditions, nor in neovascular, angle-closure, narrow-angle or congenital glaucoma, and only limited experience in thyroid eye disease, in open-angle glaucoma of pseudophakic patients and in pigmentary or pseudoexfoliative glaucoma.
Macular oedema has been reported during treatment with prostaglandin F2 analogues. Caution is recommended when using DuoTrav in aphakic patients, pseudophakic patients with a torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for cystoid macular oedema.
In patients with known predisposing risk factors for iritis/uveitis, and in patients with active intraocular inflammation, DuoTrav can be used with caution.
Excipients
DuoTrav contains propylene glycol which may cause skin irritation.
DuoTrav contains polyoxyethylene hydrogenated castor oil 40 which may cause skin reactions.
Patients must be instructed to remove contact lenses prior to application of DuoTrav and wait 15 minutes after instillation of the dose before reinsertion (see section 4.2).
Drug interactions
SmPC 4.5 Interaction with other medicinal products and other forms of interaction EU SmPC (EMA)
No specific drug interaction studies have been performed with travoprost or timolol.
There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic beta-blocker solution is administered concomitantly with oral calcium channel blockers, beta-adrenergic blocking agents, antiarrhythmics (including amiodarone), digitalis glycosides, parasympathomimetics or guanethidine.
The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta blockers.
Potentiated systemic beta blockade (e.g. decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and timolol.
Mydriasis resulting from concomitant use of ophthalmic beta blockers and adrenaline (epinephrine) has been reported occasionally.
Beta blockers may increase the hypoglycaemic effect of antidiabetic medicinal products. Beta blockers can mask the signs and symptoms of hypoglycaemia (see section 4.4).
Adverse reactions
SmPC 4.8 Undesirable effects EU SmPC (EMA)
Summary of the safety profile
In clinical studies involving 2,170 patients treated with DuoTrav the most frequently reported treatment-related adverse reaction was ocular hyperaemia (12.0%).
Tabulated summary of adverse reactions
The adverse reactions listed in the table below were observed in clinical studies or with post-marketing experience. They are ranked according to system organ class and classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), or not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in decreasing order of seriousness.
System organ class Frequency Adverse reactions
Immune system disorders Uncommon Hypersensitivity
Psychiatric disorders Rare Nervousness
Not known Hallucinations*, Depression
Nervous system disorders Uncommon Dizziness, headache
Not known Cerebrovascular accident, syncope, paraesthesia
Eye disorders Very common Ocular hyperaemia
Common Punctate keratitis, eye pain, visual disturbance,
vision blurred, dry eye, eye pruritus, ocular
discomfort, eye irritation
Uncommon Keratitis, iritis, conjunctivitis, anterior chamber
inflammation, blepharitis, photophobia, visual acuity
reduced, asthenopia, eye swelling, lacrimation
increased, erythema of eyelid, growth of eyelashes,
eye allergy, conjunctival oedema, eyelid oedema
Rare Corneal erosion, meibomianitis, conjunctival
haemorrhage, eyelid margin crusting, trichiasis,
distichiasis
Not known Macular oedema, eyelid ptosis, lid sulcus deepened,
iris hyperpigmentation, corneal disorder
Cardiac disorders Uncommon Bradycardia
Rare Arrhythmia, heart rate irregular
Not known Cardiac failure, tachycardia, chest pain, palpitations
Vascular disorders Uncommon Hypertension, hypotension
Not known Oedema peripheral
Respiratory, thoracic and Uncommon Dyspnoea, postnasal drip
mediastinal disorders Rare Dysphonia, bronchospasm, cough, throat irritation,
oropharyngeal pain, nasal discomfort
Not known Asthma
Gastrointestinal disorders Not known Dysgeusia
Hepatobiliary disorders Rare Alanine aminotransferase increased, aspartate
aminotransferase increased
Skin and subcutaneous tissue Uncommon Dermatitis contact, hypertrichosis, skin
disorders hyperpigmentation (periocular)
Rare Urticaria, skin discolouration, alopecia
Not known Rash
Musculoskeletal and Rare Pain in extremity
connective tissue disorders
Renal and urinary disorders Rare Chromaturia
General disorders and Rare Thirst, fatigue
administration site conditions
* adverse reactions observed with timolol.Additional adverse reactions that have been seen with one of the active substances and may potentially
occur with DuoTrav:
Travoprost
System organ class MedDRA preferred term
Immune system disorders Seasonal allergy
Psychiatric disorders Anxiety, insomnia
Eye disorders Uveitis, conjunctival follicles, eye discharge,
periorbital oedema, eyelids pruritus, ectropion,
cataract, iridocyclitis, ophthalmic herpes
simplex, eye inflammation, photopsia, eczema
eyelids, halo vision, hypoaesthesia eye, anterior
chamber pigmentation, mydriasis, eyelash
hyperpigmentation, eyelash thickening, visual
field defect
Ear and labyrinth disorders Vertigo, tinnitus
Vascular disorders Blood pressure diastolic decreased, blood
pressure systolic increased
Respiratory, thoracic and mediastinal disorders Asthma aggravated, rhinitis allergic, epistaxis,
respiratory disorder, nasal congestion, nasal
dryness
Gastrointestinal disorders Peptic ulcer reactivated, gastrointestinal
disorder, diarrhoea, constipation, dry mouth,
abdominal pain, nausea, vomiting
Skin and subcutaneous tissue disorders Skin exfoliation, hair texture abnormal,
dermatitis allergic, hair colour changes,
madarosis, pruritus, hair growth abnormal,
erythema
Musculoskeletal and connective tissue disorders Musculoskeletal pain, arthralgia
Renal and urinary disorders Dysuria, urinary incontinence
General disorders and administration site Asthenia
conditions
Investigations Prostatic specific antigen increased
TimololLike other topically applied ophthalmic medicinal products, timolol is absorbed into the systemic circulation. This may cause undesirable effects similar to those seen with systemic beta-blocking agents. Additional listed adverse reactions include reactions seen within the class of ophthalmic beta blockers. The incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. For information on how to reduce systemic absorption, see section 4.2.
System organ class MedDRA preferred term
Immune system disorders Systemic allergic reactions including
angioedema, urticaria, localised and generalised
rash, pruritus, anaphylaxis
Metabolism and nutrition disorders Hypoglycaemia
Psychiatric disorders Hallucinations, insomnia, nightmares, memory
loss
Nervous system disorders Cerebral ischaemia, increases in signs and
symptoms of myasthenia gravis
Eye disorders Signs and symptoms of ocular irritation (e.g.
burning, stinging, itching, tearing, redness),
choroidal detachment following filtration
surgery (see section 4.4), decreased corneal
sensitivity, diplopia
Cardiac disorders Oedema, congestive heart failure,
atrioventricular block, cardiac arrest
Vascular disorders Raynaud’s phenomenon, cold hands and feet
Gastrointestinal disorders Nausea, dyspepsia, diarrhoea, dry mouth,
abdominal pain, vomiting
Skin and subcutaneous tissue disorders Psoriasiform rash or exacerbation of psoriasis
Musculoskeletal and connective tissue disorders Myalgia
Reproductive system and breast disorders Sexual dysfunction, decreased libido
General disorders and administration site Asthenia
conditionsReporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Pregnancy considerations
SmPC 4.6 Fertility, pregnancy and lactation EU SmPC (EMA)
Women of childbearing potential/contraception
DuoTrav must not be used in women of child-bearing age/potential unless adequate contraceptive measures are in place (see section 5.3).
Pregnancy
Travoprost has harmful pharmacological effects on pregnancy and/or the foetus/newborn child.
There are no or limited amount of data from the use of DuoTrav or the individual components in pregnant women. Timolol should not be used during pregnancy unless clearly necessary.
Epidemiological studies have not revealed malformative effects but show a risk for intrauterine growth retardation when beta blockers are administered by the oral route. In addition, signs and symptoms of beta blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in the neonate when beta blockers have been administered until delivery. If DuoTrav is administered until delivery, the neonate should be carefully monitored during the first days of life.
DuoTrav should not be used during pregnancy unless clearly necessary. For information on how to reduce systemic absorption, see section 4.2.
Breast-feeding
It is unknown whether travoprost from eye drops is excreted in human breast milk. Animal studies have shown excretion of travoprost and metabolites in breast milk. Timolol is excreted in breast milk and has the potential to cause serious adverse reactions in the breast-fed infant. However, at therapeutic doses of timolol in eye drops it is not likely that sufficient amounts would be present in breast milk to produce clinical symptoms of beta blockade in the infant. For information on how to reduce systemic absorption, see section 4.2.
The use of DuoTrav by breast-feeding women is not recommended.
Fertility
There are no data on the effects of DuoTrav on human fertility. Animal studies showed no effect of travoprost on fertility at doses up to 75 times the maximum recommended human ocular dose, whereas no relevant effect of timolol was noted at this dose level.
Breastfeeding considerations
Breastfeeding is covered in SmPC 4.6 Fertility, pregnancy and lactation, under Pregnancy considerations above.
Overdose
SmPC 4.9 Overdose EU SmPC (EMA)
A topical overdose with DuoTrav is not likely to occur or to be associated with toxicity.
In case of accidental ingestion, symptoms of overdose from systemic beta blockade may include bradycardia, hypotension, bronchospasm and heart failure.
If overdose with DuoTrav occurs, treatment should be symptomatic and supportive. Timolol does not dialyse readily.
Mechanism of action
SmPC 5.1 Pharmacodynamic properties EU SmPC (EMA)
Pharmacotherapeutic group: Ophthalmologicals; Antiglaucoma preparations and miotics, ATC code: S01ED51.
Mechanism of action
DuoTrav contains two active substances: travoprost and timolol maleate. These two components lower intraocular pressure by complementary mechanisms of action and the combined effect results in additional IOP reduction compared to either compound alone.
Travoprost, a prostaglandin F2α analogue, is a full agonist which is highly selective and has a high affinity for the prostaglandin FP receptor, and reduces the intraocular pressure by increasing the outflow of aqueous humour via trabecular meshwork and uveoscleral pathways. Reduction of IOP in man starts within approximately 2 hours after administration and maximum effect is reached after 12 hours. Significant lowering of intraocular pressure can be maintained for periods exceeding 24 hours with a single dose.
Timolol is a non-selective adrenergic blocking agent that has no intrinsic sympathomimetic, direct myocardial depressant or membrane-stabilising activity. Tonography and fluorophotometry studies in man suggest that its predominant action is related to reduced aqueous humour formation and a slight increase in outflow facility.
Secondary pharmacology
Travoprost significantly increased optic nerve head blood flow in rabbits following 7 days of topical ocular administration (1.4 micrograms once daily).
Pharmacodynamic effects
Clinical effects
In a twelve-month controlled clinical study in patients with open-angle glaucoma or ocular hypertension and baseline mean IOP of 25 to 27 mmHg, the mean IOP-lowering effect of DuoTrav dosed once daily in the morning was 8 to 10 mmHg. The non-inferiority of DuoTrav as compared to latanoprost 50 micrograms/mL + timolol 5 mg/mL in the mean IOP reduction was demonstrated across all time-points at all visits.
In a three-month controlled clinical study in patients with open-angle glaucoma or ocular hypertension and baseline mean IOP of 27 to 30 mmHg, the mean IOP-lowering effect of DuoTrav dosed once daily in the morning was 9 to 12 mmHg, and was up to 2 mmHg greater than that of travoprost 40 micrograms/mL dosed once daily in the evening and 2 to 3 mmHg greater than that of timolol 5 mg/mL dosed twice daily. A statistically superior reduction in morning mean IOP (08:00, 24 hours after the last dose of DuoTrav) was observed compared to travoprost at all visits throughout the study.
In two three-month controlled clinical studies in patients with open-angle glaucoma or ocular hypertension and baseline mean IOP of 23 to 26 mmHg, the mean IOP-lowering effect of DuoTrav dosed once daily in the morning was 7 to 9 mmHg. Mean IOP reductions were non-inferior, although numerically lower, to those achieved by concomitant therapy with travoprost 40 micrograms/mL dosed once daily in the evening and timolol 5 mg/mL dosed once daily in the morning.
In a 6-week controlled clinical study in patients with open-angle glaucoma or ocular hypertension and baseline mean IOP of 24 to 26 mmHg, the mean IOP-lowering effect of DuoTrav (polyquaternium-1-preserved) dosed once daily in the morning was 8 mmHg and equivalent to that of DuoTrav (benzalkonium chloride-preserved).
Inclusion criteria were common across the studies, with the exception of the IOP entry criteria and response to previous IOP therapy. The clinical development of DuoTrav included both patients naive and on therapy. Insufficient responsiveness to monotherapy was not an inclusion criterion.
Existing data suggest that evening dosing might have some advantages as regards mean IOP reduction. Consideration should be given to patient convenience and their likely compliance when recommending morning vs. evening dosing.
Pharmacokinetics
SmPC 5.2 Pharmacokinetic properties EU SmPC (EMA)
Absorption
Travoprost and timolol are absorbed through the cornea. Travoprost is a prodrug that undergoes rapid ester hydrolysis in the cornea to the active free acid. Following once-daily administration of DuoTrav PQ in healthy subjects (N=22) for 5 days, travoprost free acid was not quantifiable in plasma samples from the majority of subjects (94.4%) and generally was not detectable one hour after dosing. When measurable (0.01 ng/mL, the assay limit of quantitation), concentrations ranged from 0.01 to 0.03 ng/mL. The mean timolol steady-state Cmax was 1.34 ng/ml and Tmax was approximately 0.69 hours after once-daily administration of DuoTrav.
Distribution
Travoprost free acid can be measured in the aqueous humour during the first few hours in animals and in human plasma only during the first hour after ocular administration of DuoTrav. Timolol can be measured in human aqueous humour after ocular administration of timolol and in plasma for up to 12 hours after ocular administration of DuoTrav.
Biotransformation
Metabolism is the major route of elimination of both travoprost and the active free acid. The systemic metabolic pathways parallel those of endogenous prostaglandin F2 which are characterised by reduction of the 13-14 double bond, oxidation of the 15-hydroxyl and -oxidative cleavages of the upper side chain.
Timolol is metabolised by two pathways. One route yields an ethanolamine side chain on the thiadiazole ring and the other gives an ethanolic side chain on the morpholine nitrogen and a second similar side chain with a carbonyl group adjacent to the nitrogen. The plasma t1/2 of timolol is 4 hours after ocular administration of DuoTrav.
Elimination
Travoprost free acid and its metabolites are mainly excreted by the kidneys. Less than 2% of an ocular dose of travoprost was recovered in urine as free acid. Timolol and its metabolites are primarily excreted by the kidneys. Approximately 20% of a timolol dose is excreted in the urine unchanged and the remainder excreted in urine as metabolites.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- European Medicines Agency. DuoTrav: EPAR, product information, Annex I, Summary of Product Characteristics [EU SmPC, last updated February 5, 2026; no US FDA label]. https://www.ema.europa.eu/en/medicines/human/EPAR/duotrav © European Medicines Agency; reproduced with acknowledgment of the source.
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .